Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Attend the 41st annual Ebony Ball Dec. 6; get tickets now
- Action required for voicemail users this Winter Break
- Submit original works to Art of STEM competition, exhibit at Kelvin Smith Library
- Learn about impact of design in today’s corporate world at Dec. 2 presentation
- Platelet mimicry technology halts bleeding faster, may have broad use in medicine